1. Home
  2. KMDA

as of 10-01-2026 3:40pm EST

$8.22
$0.24
-2.84%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.

Founded: 1990 Country:
Israel
Israel
Employees: N/A City: N/A
Market Cap: 460.3M IPO Year: 2013
Target Price: $13.50 AVG Volume (30 days): 125.8K
Analyst Decision: Strong Buy Number of Analysts: 3
Dividend Yield:
4.96%
Dividend Payout Frequency: N/A
EPS: N/A EPS Growth: N/A
52 Week Low/High: $6.50 - $9.35 Next Earning Date: 11-09-2026
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): 9.5% Revenue Growth (next year): 12.63%
P/E Ratio: 24.59 Index: N/A
Free Cash Flow: N/A FCF Growth: -16.70%

Stock Insider Trading Activity of Kamada Ltd. (KMDA)

Tsur David

Director

Sell
KMDA Sep 14, 2026

Avg Cost/Share

$8.18

Shares

22,827

Total Value

$186,724.86

Owned After

407,929

SEC Form 4

Tsur David

Director

Sell
KMDA Sep 9, 2026

Avg Cost/Share

$8.26

Shares

175

Total Value

$1,445.50

Owned After

407,929

SEC Form 4

Tsur David

Director

Sell
KMDA Sep 8, 2026

Avg Cost/Share

$8.26

Shares

162,760

Total Value

$1,344,397.60

Owned After

407,929

SEC Form 4

Tsur David

Director

Sell
KMDA Sep 7, 2026

Avg Cost/Share

$8.28

Shares

14,238

Total Value

$117,890.64

Owned After

407,929

SEC Form 4

Share on Social Networks: